Category: 4733-39-5

4733-39-5, 2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,4733-39-5

Synthesis of the hexafluorophosphate salt of the ruthenium complexes 1-6 and 8 The ruthenium complex 1(PF6)2 was synthesized by the following procedure. [Ru(bpy)2Cl2]¡¤ (0.242 g, 0.5 mmol) and phen (0.090 g, 0.5 mmol) were mixed in ethylene glycol (15 ml). After the suspended mixture was refluxed for 7 min in the microwave oven under purging nitrogen atmosphere. The reaction mixture was cooled to room temperature and then the saturated aqueous solution of KPF6 (20 ml) was added. An orange-red product 1 began to precipitate and was collected in 60% yield. Complexes 2, 3, 4, 5, 6, and 8 were synthesized in the similar way. Complex 1¡¤(PF6)2: ESI-MS (in CH3CN, positive): m/z = 738.95 ([M-(PF6)]+ requires 738.61). 297.01 ([M]2+ requires 296.82); Anal. Calcd for RuC32H24N6P2F12: C, 43.50; H, 2.74; N, 9.51; Found: C, 43.02; H, 3.29; N, 9.40; 1H NMR (400 MHz, CD3CN): delta 7.20 (dd, 1H, J = 5.6 Hz and 6.8 Hz), 7.43 (dd, 1H, J = 6.4 Hz and 6.8 Hz), 7.52 (d, 1H, J = 5.2 Hz), 7.72 (dd, 1H, J = 4.8 Hz and 3.2 Hz), 7.83 (d, 1H, J = 5.6 Hz), 7.97 (dd, 1H, J = 7.6 Hz and 8.0 Hz), 8.07 (d, 1H, J = 5.2 Hz), 8.09 (d, 1H, J = 8.0 Hz), 8.23 (s, 1H), 8.47 (d, 1H, J = 8.0 Hz), 8.51 (d, 1H, J = 8.0 Hz), 8.60 (d, 1H, J = 8.4 Hz).

As the paragraph descriping shows that 4733-39-5 is playing an increasingly important role.

Reference£º
Article; Yoshikawa, Naokazu; Yamabe, Shinichi; Sakaki, Shigeyoshi; Kanehisa, Nobuko; Inoue, Tsuyoshi; Takashima, Hiroshi; Journal of Molecular Structure; vol. 1094; (2015); p. 98 – 108;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4733-39-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4733-39-5,2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

[CuI(MeCN)4](ClO4) (50mg, 0.15mmol), PPh3 (80.4mg, 0.30mmol) and Ph2dmp (60.7mg, 0.18mmol) in MeCN (15ml) are stirred at room temperature for 1h. Slow evaporation of a MeCN solution of 4 afforded analytically pure complex as yellow crystalline solid. Yield (93.4mg, 62.9%). Elemental analysis for C62H50ClCuN2O4P2: calcd. C 71.06, H 4.81, N 2.67%; found: C 71.12, H 4.90, N 2.62%. Selected IR (KBr, cm-1): v(Cl-O) 1110. ESI-MS (positive): m/z 947 (M+). 1H NMR (300MHz, CDCl3): delta 7.98 (s, 2H, Phen H); 7.60 (m, 6H, phenyl H); 7.57-7.53 (m, 4H, phenyl H); 7.44 (s, 2H, phen H); 7.38-7.42 (m, 6H, phenyl H); 7.26-7.21 (m, 24H, phenyl H); 2.31 (s, 6H, -CH3). 31P{1H} NMR (162MHz, CDCl3): delta 0.87 (s, PPh3). UV/Vis (CH3CN): lambdamax/nm (epsilon/mol-1dm3cm-1): 228 (68830), 287 (53890), 369 sh (3950).

4733-39-5 2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline 65149, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Hu, Lin-Li; Shen, Chang; Chu, Wing-Kin; Xiang, Jing; Yu, Fei; Xiang, Ge; Nie, Yan; Kwok, Chun-Leung; Leung, Chi-Fai; Ko, Chi-Chiu; Polyhedron; vol. 127; (2017); p. 203 – 211;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4733-39-5,2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: 1a-j were prepared photolytically using a procedure adapted from the literature;[25] the synthesis of 1j is presented below and typifies all such syntheses performed in this work. W(CO)6(0.550 g, 1.56 mmol) was dissolved in 50mL dry tetrahydrofuran(Pharmco) and degassed in a round-bottom flask. The resulting solution was illuminated with a 100-W mercury arc lamp until nearly complete conversion to W(CO)5(THF) had been effected[26] as determined by infrared spectroscopy; this normally required 3 to 4 h of constant illumination. To the resulting yellowish-green solution was added a slight molar excess of dmp (0.347 g, 1.64 mmol) under constant stirring and nitrogen purging; this resulted in a rapid colour change and eventual precipitation of the desired product. After 30 min, the precipitate was isolated and washed with additional THF; the crude product was purified by recrystallization from dichloromethane/hexanes. The product (0.516 g, 1.02 mmol, 65%yield) consisted of brick-red crystals and its identity was confirmed by IR spectroscopy. Most of the compounds synthesized exhibited deep-red luminescence as solids.

4733-39-5, The synthetic route of 4733-39-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Bullock, John P.; Lee, Chong-Yong; Hagan, Brian; Madhani, Humair; Ulrich, John; Australian Journal of Chemistry; vol. 70; 9; (2017); p. 1006 – 1015;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4733-39-5,2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.,4733-39-5

(1) Synthesis of 2,9-bis(tosylaminomethyl)-4,7-diphenyl-1,10-phenanthroline (x) 2,9-Bis(aminomethyl)-4,7-diphenyl-1,10-phenanthroline perchlorate (w) (2.36 g, 4 mmol), which was synthesised from 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline according to the method described in J. Heterocyclic Chem., 18, 599 (1981), was dissolved in pyridine (20 ml). p-Toluene sulfonyl chloride (1.6 g, 8 mmol) was added to the solution with cooling using an ice bath, and the reaction mixture was stirred at room temperature for 3 hours. The resulting solution was poured into water (200 ml) and extracted with chloroform (200 ml). The chloroform layer was chromatographed on a silica gel column using chloroform/methanol as eluent to give the desired 2,9-bis(tosylaminomethyl)-4,7-diphenyl-1,10-phenanthroline (x) (yield=1.54 g).

4733-39-5 2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline 65149, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Dojindo Laboratories; Mochida Pharmaceutical Co., Ltd.; US5262526; (1993); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4733-39-5,2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: A mixture of (CBT)2Ir(m-Cl)2Ir(CBT)2 (0.84 g, 0.40 mmol) and1,10-phenanthroline (phen, 0.17 g, 0.84 mmol) in glycol (30 mL)wasstirred at 150 C in argon for 16 h. After being cooled to room temperature,an orange-red solution was obtained, and then 10 mLaqueous solution ofNH4PF6 (0.4 mol L1)was added in. The resultantorange floccules were filtered, washed withwater and then dried invacuum. The pure product was obtained by silica gel column chromatography,eluting with a mixture of CH2Cl2 and acetonitrile (10:1,volume ratio). Yield 90.3% (0.97 g, 0.72 mmol)

4733-39-5, The synthetic route of 4733-39-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Tang, Huaijun; Chen, Zeyu; Wei, Liying; Miao, Jingsheng; Meng, Guoyun; He, Yonghui; Wu, Hongbin; Dyes and Pigments; vol. 131; (2016); p. 340 – 348;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI